Best Gastroenterology Companies in Israel
The 32 best Gastroenterology companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Motus Gi.
- Gastroenterology Market Projected to Reach USD 53.10 Billion by 2031,
Ranked: Best Gastroenterology companies in Israel
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Adar Biotech Medical devices for GI drug delivery enhancement, GI infections & head lice treatment | — | — | — | Yinon Shlomi Founder & CEO | Unfunded | — | — |
| 2 | E-Motion Medical Developer of medical technology intended to treat gastrointestinal dysmotility. | — | — | 2 | — | Deadpooled | — | — |
| 3 | EndoAid Silicone-made colonoscope accesory for the improved detection of polyps and adenomas | — | — | 5 | Omer Shezifi Co-Founder & Vp R&D | Unfunded | 14 patents Endoscopic sleeve and protective glove devices for minimally invasive gastrointestinal procedures | — |
| 4 | Etrog Medical Developed a device for colonoscopy without early preparation | — | — | — | Benny Levin Founder | Deadpooled | — | — |
| 5 | Exalenz Bioscience Breath gas analysis to detect H pylori infection and diagnose Gastric and hepatocellular cancer | — | — | 2 | — | Acquired | 31 patents Non‑invasive breath‑based diagnostics for liver disease and hepatocellular carcinoma | — |
| 6 | Gema Medical 3D scanner for the real time monitoring of activities of the stomach | — | — | — | Matan BenDavid Co-Founder | Deadpooled | — | — |
| 7 | Gema Medical Electro-mechanical activity mapping device for gastric motility disorders | — | — | — | Eyal Bressler Founder | Deadpooled | — | — |
| 8 | GerdCare Developer of non-invasive devices to treat gastroesophageal reflux disease | — | — | 3 | Giora Arbel CEO | Funding Raised | — | — |
Top 12 Gastroenterology companies in Israel
#1
Public · Ramat Gan, Tel Aviv District · founded 2009 · 183 employees$13.5Mraised▾
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases. The company is focusing on the development of proprietary, orally-administered, small molecule drugs for the treatment of multiple diseases. The company’s product pipeline includes RHB-204, RHB-104, RHB-102, and RHB-106 for H. pylori infections, Crohn's disease, Gastroenteritis gastritis, solid tumor, pancreatic cancer, Migraine, and other diseases.
- Jan 2024Post IPO$10M
- Oct 2023Post IPO$4M
- Aug 2023Post IPO$2.7M
- Sep 2020Grant (prize money)$300K
#2
Public · Tirat Carmel, Haifa District · founded 2008 · 23 employees$30.1Mraised▾
Motus-GI's first product the Pure-Vu, is designed to clean a poorly prepped colon during a colonoscopy procedure, which may reduce the dependency on a successful pre-procedural prep regimen to gain clear visualization of the colon mucosa. The system consists of a disposable single-use over-sleeve and a workstation controller. The disposable over-sleeve fits easily over standard colonoscopes and is connected to the workstation. Pure-Vu does not interfere with the working channel or the navigation or advancement of the colonoscope. The workstation controls a novel irrigation technology that creates a pulsed mixture of water and air through 4 jets to loosen fecal material and an efficient evacuation cycle that effectively removes considerable colon content. It also has an auto-purge technology to prevent clogging.
- May 2023Post IPO—
- Feb 2017Series A$30M
- Nov 2016Seed$82.5K
#3
Series A · Kfar Saba, Central District · founded 2010 · 16 employees$8Mraised▾
Developer of an intraluminal bypass device designed to reduce the rate of diverting stomas and their related complications. The company's devices contain an alternative to divert stoma by providing a temporary intraluminal bypass which helps in reducing the contact of fecal materials with the anastomotic site, reducing the life-threatening symptoms related to clinical anastomotic leaks, enabling doctors to maintain patients' well-being in a safe and effective manner and minimizing post-operative complications for a comfortable recovery.
- Jun 2022Grant (prize money)$2.4M
- Sep 2017Series A$8M
- Mar 2017Grant (prize money)$52.7K
- Jan 2017Grant (prize money)$52.1K
#4
Series E · Yokneam Illit, Northern District · founded 2007 · 18 employees$25Mraised▾
Vibrant is a developer of chemical-free vibrating capsules for the treatment of constipation. The capsule induces vibration inside the GI tract mechanically induces peristalsis, thus aiding in treating constipated patients without side effects. It claims that the capsule targets the physiological parameters of constipation and induces natural bowel activity without using chemical supplements or changing the delicate internal body equilibrium.
- Mar 2021Series E$7.5M
- 2014Series A—
#5
Seed · Rehovot, Central District · founded 2014 · 27 employees$4.7Mraised▾
Developer of microbiome-based therapeutics to treat various diseases. The company's product pipeline for cancer vaginal dysbiosis and the gastrointestinal solution is under the preclinical phase. It uses fermentation and formulation technology for the development of therapeutics. The company's technology platform includes MyCrobe (Single strain fermentation and formulation technology), SuperDonor (microbiome production and recovery technology), SuperDonor Select (Next-generation multi-strain technology), and MyLiveIn (AI-enabled design platform)
- May 2022Grant (prize money)$53.8K
- Feb 2021Seed—
- Oct 2020Grant (prize money)$2.4M
- Jun 2020Grant (prize money)$2.2M
#6
Public · Haifa, Haifa District · founded 2005 · 81 employees$9.9Mraised▾
Developer of imaging capsules for colorectal cancer screening. The Check-Cap device requires no bowel preparation/invasive procedures and detects polyps with a high degree of sensitivity. According to the company, the technology has been proven in animals. Check-Cap's technology offers CRC screening through a structural exam.
- Jul 2020Post IPO$9.6M
- May 2020Post IPO$3M
- Apr 2020Post IPO$4.5M
- Apr 2020Post IPO$4M
#7
Series B · Ra anana, Center District · founded 2005 · 13 employees$14.5Mraised▾
Smart Medical systems produces medical devices for gastroenterology and GI endoscopy. Its G-EYE and NaviAid product families have both FDA approval and the european CE Mark. The G-EYE endoscope consists of a standard endoscope, having a permanently integrated, reusable balloon at its bending section which allows for increased diagnostic yield during colonoscopy, endoscope stabilization during therapy, and extended operating range in the colon, small bowel and entire GI tract. The NaviAid AB (Advancing Balloon) device provides for on demand Ileoscopy / upper enteroscopy while using standard endoscopes. It is an on-demand device, which can be introduced through the tool channel of the endoscope during a procedure (colonoscopy or EGD), without the need for pre-mounting or interrupting the normal course of examination. Once inflated ahead of the endoscope and anchored in the bowel, the device is used as a rail on which the endoscope is advanced, replacing pushing by guidance. The Navi Aid inflation systems consist of a system wherein the Balloon inflation pressure is regulated and continuously monitored, to ensure optimal anchoring of the inflated balloon to the intestinal walls whil
- Feb 2018Series B$8M
- Apr 2014Series A$6.5M
#8
Seed · Misgav, Northern District · founded 2014 · 3 employees$4.2Mraised▾
Provider of an enteral feeding device for the treatment of gastrointestinal disorders. The company product includes a PEG device disposable feeding tube with an internal bumper that enables to prevent dislodgment and breaks apart for trauma.
#9
Deadpooled · Netanya, Central District · founded 1996 · 47 employees$18.5Mraised▾
NovoGI, formerly NiTi Surgical Solutions, provides medical devices for GI disease management. Offers nitinol-based compression anastomosis devices for treating patients undergoing colorectal resection procedures. CE-marked and FDA-cleared surgical devices. Its R&D, and manufacturing facilities are in Netanya, Israel and the US headquarter is in Atlanta, Georgia, and European headquarters are in Paris, and France.
#10
Series A · Or Yehuda, Tel Aviv · founded 2016 · 8 employees$2.7Mraised▾
Provider of AI-powered IoT devices for diagnostics. It offers an IoT device that can be attached to a toilet bowl that autonomously scans human waste using optical sensors. It employs AI algorithms that analyse a patient’s medical history to provide personalized diagnostics and biofeedback. Its features include health information system integration, integrable mobile application, data encryption, configurable system alerts on possible health deviations, real-time analysis, lab-grade data accuracy, cloud storage, and multiple test categories.
- Jun 2021Series A—
- Mar 2018Grant (prize money)$61.6K
- Oct 2017Grant (prize money)$59K
- Jan 2017Grant (prize money)$52.8K
#11
Series A · Ramat Gan, Tel Aviv District · founded 2004 · 25 employees$10Mraised▾
GIview develops devices for diagnosis and treatment of GI disorders. Colonoscope is designed for colorectal cancer screening. Its product, the Aer-O-Scope is a self-propelled, disposable colonoscope with 360° omni-directional visualization. The pneumatic self-propulsion mechanism uses balloons and low pressure CO2 gas for self-propelled intubation. It is connected to the Aer-O-Scope work station, which operates the disposable scanner.
- May 2006Series A$10M
#12
Seed · Misgav, Northern District · founded 2009 · 8 employees$1Mraised▾
Stimatix GI formerly known as Colongate offers medical devices to control stomas after a colostomy. Offers AOS-C2000, a non-surgical and simple to use solution for continence and control. It is a bi-component system and includes a CapsuleCap and a CapHolder. The Company operates under the supervision of the Misgav Venture Accelerator.
- Mar 2011Seed$1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Gastroenterology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.